This clinical trial is focused on studying a condition known as Hemophilia A, which is a genetic disorder that affects the blood’s ability to clot properly. The treatment being investigated in this study is called efanesoctocog alfa, also known by its code name BIVV001. This medication is designed to help manage bleeding episodes in patients with severe Hemophilia A by providing a replacement for a missing protein that is crucial for blood clotting.

The purpose of this study is to gather more information about the safety and effectiveness of efanesoctocog alfa in patients who have already participated in a previous trial with this treatment. Participants will receive the medication through an intravenous injection, which means it is administered directly into a vein. The study will monitor how well the treatment works in preventing bleeding episodes and how well it is tolerated by the patients over a period of time.

Throughout the study, participants will continue to receive efanesoctocog alfa as a prophylactic treatment, which means it is given regularly to prevent bleeding rather than treating it after it occurs. The study aims to ensure that patients have continued access to this treatment and to collect further data on its long-term use. Participants will be closely monitored for any side effects or adverse events to ensure their safety while receiving the treatment.